An interventional study of Mobile Research App (MRA) and SOC/validated delivery of the speech perception test material in Hearing Loss, sponsored by Cochlear. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Cochlear · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hearing Loss by Cochlear — 5 open to participants now, 12 under way, none of them phase 3. Hearing Loss · Cochlear.
Among the 50 studies in Hearing Loss by Cochlear, this one is the 16th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2024, is one of 43 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 38th registered.
797 studies on the registry are indexed under Hearing Loss; 195 are open to participants now.
Browse Hearing Loss studies →5 of the 50 studies in Hearing Loss by Cochlear are open now, in 6 countries. Recruiting first, the newest first:
Cochlear · Sites in Belgium, Spain
Ages 18+
Cochlear · Sites in Belgium, Netherlands
Ages 18+
Cochlear · Sites in Australia
Ages 18+
Cochlear · Sites in Germany
Ages 18+
Cochlear · Sites in United States, Australia
Ages 18+
By country, each count listing its studies:
Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 46 is close to the median of 44 across 562 interventional studies indexed under Hearing Loss.
Median enrollment 32 across the 43 interventional studies, 153 across the 7 observational. Of the 37 that completed or were terminated, 27 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cochlear is the lead sponsor of 92 studies on the registry; 9 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
6 of the studies in Hearing Loss by Cochlear that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07139327CochlearA Pivotal Study to Evaluate the Efficacy and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults | 2027-04 |
| NCT06098482CochlearAn Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App | 2027-05-02 |
| NCT06805175CochlearA Study to Evaluate the Safety and Performance of a Vestibular Implant in Adults to Provide Balance Restoration | 2027-06 |
| NCT06641999CochlearEvaluating How a Tinnitus Implant Affects Tinnitus Loudness in Adults With Chronic Tinnitus and Varying Levels of Hearing Loss | 2027-07 |
| NCT07287124CochlearA Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Hearing Loss by Cochlear, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cochlear implant recipients will participate in this arm (sub-investigation AI5841A).
Device: Mobile Research App (MRA) · Other: SOC/validated delivery of the speech perception test material
Cochlear implant and hearing aid recipients will participate in this arm (sub-investigation AI5841B).
Device: Mobile Research App (MRA) · Other: SOC/validated delivery of the speech perception test material
The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.
This involves the delivery of speech perception test material in the sound booth in a clinic.
Percent correct performance for the test and retest runs of speech perception ability
To determine if test-retest reliability with a correlation greater than or equal to 0.8 can be achieved for speech perception ability measured on the MRA outside the sound booth, percent correct performance for the test and retest runs of the speech perception ability will be compared. Scoring: Percentage correct Range: 0-100%, higher scores equal better performance
Time frame: 1 day - immediately post screening.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.
Of 126 industry-sponsored interventional studies with no phase under Hearing Loss, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 38 months is above that.
Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.